Crinetics Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Crinetics Pharmaceuticals' es R. Struthers , nombrado en Dec 2008, tiene una permanencia de 15.33 años. compensación anual total es $5.60M, compuesta por 10.5% salario y 89.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.31% de las acciones de la empresa, por valor de $45.18M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.6 años, respectivamente.
Información clave
R. Struthers
Chief Executive Officer (CEO)
US$5.6m
Compensación total
| Porcentaje del salario del CEO | 10.5% |
| Permanencia del CEO | 15.3yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27
Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Compensación vs. Mercado: La compensación total ($USD5.60M) de R. está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de R. ha aumentado mientras la empresa no es rentable.
CEO
R. Struthers (61 yo)
15.3yrs
Permanencia
US$5,602,127
Compensación
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 15.3yrs | US$5.60m | 1.31% $ 43.5m | |
| Founder & Chief Scientific Officer | 2.5yrs | US$2.08m | 0.056% $ 1.9m | |
| Chief Financial Officer | 6.3yrs | US$2.31m | 0.073% $ 2.4m | |
| Chief Commercial Officer | 2.2yrs | US$2.84m | 0.0023% $ 75.0k | |
| Chief Development Officer | 1.6yrs | US$3.61m | 0.0018% $ 60.0k | |
| Chief Operating Officer | 2.6yrs | US$2.98m | 0.0064% $ 211.9k | |
| General Counsel & Corporate Secretary | 2.8yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 3.9yrs | sin datos | sin datos | |
| Chief Medical Officer | 5.8yrs | US$1.55m | 0.017% $ 554.2k | |
| Head of Intellectual Property | no data | sin datos | sin datos | |
| Chief Business Officer | 2.1yrs | sin datos | sin datos | |
| Vice President of Clinical Endocrinology | 3.4yrs | sin datos | sin datos |
2.8yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRNX se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 15.4yrs | US$5.60m | 1.31% $ 43.5m | |
| Independent Chairman of the Board | 8.5yrs | US$316.40k | 0.13% $ 4.2m | |
| Independent Director | 6.2yrs | US$293.40k | 0.016% $ 533.7k | |
| Independent Director | 3.6yrs | US$277.40k | sin datos | |
| Independent Director | 2.3yrs | US$879.80k | 0.0064% $ 212.9k | |
| Independent Director | 6.2yrs | US$279.90k | sin datos | |
| Independent Director | 4.8yrs | US$289.40k | 0.0077% $ 255.4k | |
| Independent Director | 2.1yrs | US$769.98k | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos |
3.6yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de CRNX se considera experimentada (3.6 años de antigüedad promedio).